icon-folder.gif   Conference Reports for NATAP  
 
  EASL 47th Annual Meeting
April 18th - 22nd 2012
Barcelona, Spain
Back grey_arrow_rt.gif
 
 
 
A 12-Week Interferon-Free Regimen of ABT-450/r, ABT-072, and Ribavirin was Well Tolerated and Achieved Sustained Virologic Response in 91% Treatment-Na´ve HCV IL28B-CC Genotype-1-Infected Subjects
 
 
  Eric Lawitz1, Fred Poordad2, Kris V. Kowdley3, Donald Jensen4, Daniel E. Cohen5, Sara Siggelkow5, Karen Wikstrom5, Lois Larsen5, Rajeev M. Menon5, Thomas Podsadecki5, Barry Bernstein5
 
1: Alamo Medical Research, San Antonio, TX, 2: Cedars-Sinai Medical Center, Los Angeles, CA, 3: Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, 4: Center for Liver Diseases, University of Chicago Medical Center Chicago, Chicago, IL 5: Abbott, Abbott Park, IL

Pharm1.gif

Pharm2.gif

Pharm3.gif

Pharm4.gif

Pharm5.gif

Pharm6.gif